- Home
- CHEK vs CNSP Comparison
CHEK vs CNSP Comparison
Compare CHEK & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHEK
- CNSP
- Stock Information
- Founded
- CHEK 2004
- CNSP 2017
- Country
- CHEK Israel
- CNSP United States
- Employees
- CHEK N/A
- CNSP N/A
- Industry
- CHEK Medical Electronics
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- CHEK Health Care
- CNSP Health Care
- Exchange
- CHEK Nasdaq
- CNSP Nasdaq
- Market Cap
- CHEK 4.5M
- CNSP 4.0M
- IPO Year
- CHEK 2015
- CNSP 2019
- Fundamental
- Price
- CHEK $0.67
- CNSP $5.66
- Analyst Decision
- CHEK
- CNSP Hold
- Analyst Count
- CHEK 0
- CNSP 1
- Target Price
- CHEK N/A
- CNSP N/A
- AVG Volume (30 Days)
- CHEK 26.5K
- CNSP 40.3K
- Earning Date
- CHEK 08-26-2025
- CNSP 08-14-2025
- Dividend Yield
- CHEK N/A
- CNSP N/A
- EPS Growth
- CHEK N/A
- CNSP N/A
- EPS
- CHEK N/A
- CNSP N/A
- Revenue
- CHEK N/A
- CNSP N/A
- Revenue This Year
- CHEK N/A
- CNSP N/A
- Revenue Next Year
- CHEK N/A
- CNSP N/A
- P/E Ratio
- CHEK N/A
- CNSP N/A
- Revenue Growth
- CHEK N/A
- CNSP N/A
- 52 Week Low
- CHEK $0.56
- CNSP $4.93
- 52 Week High
- CHEK $3.04
- CNSP $221.94
- Technical
- Relative Strength Index (RSI)
- CHEK 40.79
- CNSP 21.28
- Support Level
- CHEK $0.59
- CNSP $6.28
- Resistance Level
- CHEK $0.68
- CNSP $7.75
- Average True Range (ATR)
- CHEK 0.04
- CNSP 0.78
- MACD
- CHEK 0.00
- CNSP -0.13
- Stochastic Oscillator
- CHEK 46.45
- CNSP 3.96
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.